

Lumito's technology enables quantification of low abundant cells

Lumito AB (publ) ("Lumito" or the "Company") today announces new results from its collaboration with Truly Labs AB ("Truly Labs"), demonstrating that Lumito's tissue analysis technology enables significantly improved detection of low abundant, "rare", cells compared to conventional staining methods. The results were presented at the Pharma Outsourcing conference, organised by Life Science Sweden, on December 2, 2025, in Stockholm.

In the presented work, eosinophils (a cell type that is often difficult to identify reliably using traditional histological stains), were clearly and distinctly visualised using Lumito's SCIZYS platform and upconverting nanoparticles (UCNPs). The technology provided high contrast and precise localisation, making the cells easily identifiable even in complex tissue environments.

The ability to detect and quantify rare cell populations is an important challenge in both research and drug development, where small but biologically relevant changes can otherwise be overlooked. These results further confirm that Lumito's technology can extract more reliable and detailed information from tissue samples than conventional methods.

"Highlighting rare cells in tissue samples has long been a challenge. In some of our asthma studies, identifying key cells such as eosinophils proved difficult despite multiple approaches. When we applied Lumito's SCIZYS platform, the results were striking, these cells became easy to see and simple to quantify. We are confident our customers will be just as impressed as we are," says Karin von Wachenfeldt, CEO Truly Labs.

The findings build on the collaboration between Lumito and Truly Labs, established in December 2024, that includes pilot studies and method development with an aim to include the SCIZYS technology in Truly Labs' customer offering. The demonstration at Pharma Outsourcing highlights a new, concrete application area where Lumito's technology can create immediate value.

Lumito's SCIZYS platform eliminates background interference and enables high sensitivity detection of biomarkers in tissue and a wide dynamic range, making it particularly well suited for detecting rare cells and subtle biological signals. With this capability now validated and demonstrated, Lumito strengthens its position as a provider of advanced tissue analysis solutions.

For further information, please contact:

Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68

About Lumito

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

About Truly Labs

Truly Labs AB is a Contract Research Organization (CRO) providing customized in vitro and in vivo services to its customers. Truly Labs was founded in January 2015 as a subsidiary of Truly Translational AB. The Truly Labs' team has a solid track record with scientific and experimental expertise and experience from drug research & development in both large pharma and biotech, and extensive experience of working with both small molecules and biologics. Truly Labs' key therapeutic areas are inflammation, respiratory diseases, oncology and autoimmune diseases where we offer state of the art in vitro and in vivo technologies. www.trulytranslational.com

Attachments

[Lumito's technology enables quantification of low abundant cells](#)